trending Market Intelligence /marketintelligence/en/news-insights/trending/MmM6KBrDHkFmAF18Tu7YBQ2 content esgSubNav
In This List

CHMP recommends Bristol-Myers' Yervoy for pediatric skin cancer patients

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


CHMP recommends Bristol-Myers' Yervoy for pediatric skin cancer patients

Bristol-Myers Squibb Co. said a panel of the European Medicines Agency recommended the approval of Yervoy for treating skin cancer in pediatric patients.

The backing from the EMA's Committee for Medicinal Products for Human Use covers the use of Yervoy, or ipilimumab, in unresectable or metastatic melanoma patients aged 12 years and older.

Bristol-Myers' Yervoy is already approved for multiple cancer indications. The monoclonal antibody works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.